US4808402A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method and compositions for modulating neovascularization
Assignee: Genentech Inc
•
Filing: 1987-05-29
•
Granted: 1989-02-28
•
Expires: 2007-05-29
Abstract
Abstract Tumor necrosis factors possess the unexpected ability to induce angiogenesis, or neovascularization. Novel methods and TNF-containing compositions and articles are provided for the induction of neovascularization and rapid wound healing.
Inventors
- 👤 Samuel J. Leibovich
- 👤 Peter J. Polverini
- 👤 H. Michael Shepard
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 18:28
CPC Classifications
A; A61; A61L; A61L17/00; A61L17/005; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/191; A61L15/00; A61L15/16; A61L15/22; A61L15/32; A61L26/00; A61L26/0061; A61L26/0066; A61L2300/00; A61L2300/40; A61L2300/412; A61L2300/426
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
26 words
A method for accelerating the neovascularization of a wound which comprises applying to the wound an angiogenically effective dose of a composition comprising tumor necrosis factor.
Claim 2
Independent Claim
26 words
A method for accelerating the neovascularization of a wound which comprises applying to the wound an angiogenically effective dose of a composition comprising tumor necrosis factor.
Claim 3
Dependent Claim
25 words
The method of claim 1 wherein the composition is applied topically by direct contact with the wound and the wound is a fresh surgical incision.
Claim 4
Dependent Claim
14 words
The method of claim 2 wherein the composition further comprises a sustained release carrier.
Claim 5
Dependent Claim
13 words
The method of claim 3 wherein the composition further comprises a bioerodible polymer.
Claim 6
Dependent Claim
12 words
The method of claim 4 wherein the bioerodible polymer is a polylactide.
Claim 7
Dependent Claim
11 words
The method of claim 2 wherein the composition further comprises collagen.
Claim 8
Dependent Claim
11 words
The method of claim 2 wherein the TNF is human TNF-α.
Claim 9
Dependent Claim
19 words
The method of claim 2 wherein the wound is a burn and the composition further comprises a skin graft.
Claim 10
Dependent Claim
25 words
The method of claim 2 further comprising administering to the wound a substance selected from the group of growth factors, antibiotics, debridement agents and angiogenin.
Claim 11
Dependent Claim
19 words
The method of claim 9 wherein the growth factor is TGF-α, TGF-β, fibroblast growth factor, or epidermal growth factor.
Claim 12
Dependent Claim
12 words
The method of claim 9 wherein the antibiotic is a silver salt.
Claim 13
Dependent Claim
14 words
The method of claim 2 wherein the wound is a diabetic or decubitus ulcer.
Claim 14
Dependent Claim
14 words
The method of claim 3 wherein the sustained release carrier is an oleaginous salve.
Claim 15
Dependent Claim
15 words
The method of claim 3 wherein the carrier is in the form of a film.
Claim 16
Dependent Claim
17 words
The method of claim 1 wherein the TNF is applied to the wound by substantially continuous irrigation.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-02-28 | 1992-08-29 | 1993-02-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-02-28 | 1996-08-29 | 1997-02-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-02-28 | 2000-08-29 | 2001-02-28 | $7700.00 | Window Closed / Lapsed |